Standard GLP-1 eligibility thresholds - based on the FDA-approved drug labeling for Wegovy and Zepbound, which guides how clinicians think about the category - generally include a BMI of 30 or higher (obese), or a BMI of 27 or higher with at least one weight-related comorbidity such as high blood pressure, high cholesterol, or type 2 diabetes
These can include nausea, vomiting of undigested food, abdominal pain, bloating, severe dehydration, a sense of fullness after only a few bites, solidification of undigested food within the stomach, acid reflux, fluctuating blood sugar readings, reduced appetite, weight loss, undernutrition, and a diminished overall quality of life
Given the drugs high list price, though, its natural to wonder when generic Wegovy will be available
L- -
Take protein with or shortly after injection
The TECs is the most vulnerable cells to ferroptosis in CKD